RSS

CYDY CytoDyn Inc

Mod: mightycydy Asst: HHIGambler,CaptnAmerca
Last Post: 2:42 AM
Followers: 439
Posts Today: 1
Views Today: 64072

CYDY Stock Quote & Tools

$0.2054 ▲ +0.0054 (+2.69%) As of Oct 15, 3:59 PM EDT
Last0.2054
$ Chg0.0054
Open0.2000
High0.2090
Beta1.4964
Year High0.397
Market Cap301.80M
P/B Ratio-2.68
EPS-0.04
Avg Vol (30d)1.57M
Volume3.28M
% Chg+2.69%
Prev Close0.2000
Low0.1971
VWAP0.20198
Year Low0.183
Total Shares1.47B
Shares Out1.47B
Float1.36B
ExchangeOTCQB
Healthcare Biotechnology & Life Sciences
Company Profile Buy Rating Time & Sales News Filings Financials

CYDY Stock Message Board Discussion

3 Pinned Posts
Leronlimab (Pro 140) Cliff Notes What is it? Leronlimab is a humanized monoclo (43) by trding
Leronlimab Regulator List (a work in progress) = upregulation = downregulation a-SMA (21) by ohm20
EIND: Information to Submit to Doctors Leronlimab a humanized monoclonal antibody binds CCR5, (38) by ohm20
  1. VegasorBust

    https://apple.news/ABI0TJn_sS7SlDLwSIqLOhA Too bad we have to wait until the end of July to

    (3)
  2. Shelly2626

    Definitely Chiral should know how to manage the system It is still a great opportunity and I

    (6)
  3. CDiddy

    I hope so. The revenue could be helpful.

    (1)
  4. nothingspecial

    As to PI being on the back burner, I think it's just a matter of the politics there slowing things

    (4)
  5. nothingspecial

    Found that a little confusing as well. My guess is that after 56 days of suffering, LL arm only

    (4)
  6. nmbr1stckpckr

    Just listened to the cc. Sounds like Dr. Reknor (sp?) is who we needed, not Mahbooby. Having

    (7)
  7. nothingspecial

    This cc was so different. Lots of positives & much to discuss. Many possibilities going forward.

    (6)
  8. Riztheinvestor

    Just looked over the 8k, it says Q4 of this year Long-Haulers competed. Jeez that seems optimistic

    (2)
  9. fsoalex

    To my fellow Vancouver and Portland area Cydyers. KOIN 6 just did a segment on longhaulers

    (3)
  10. RTB

    Wow, this is stunning, and in a good way. I can't believe that they did a morning press release,

    (16)
  11. skipper1072

    Thanks. My guess is there will be demands to now include CYDY given these

  12. PTM1

    Did anyone ask or mention the size or status of the purchase order from the PI?

  13. Number1Stocker

    I think someone suggested possibly the data wasn't ready.

    (2)
  14. skipper1072

    How can CYDY not be a presenter at the Long Haulers' conference? I asked that question for the

    (1)
  15. Number1Stocker

    I am going to throw this out there. If there was to be no resolution between the 13 group and

    (2)
  16. Kevin0461

    Great stuff!!! Thank you for posting!!

  17. Kevin0461

    I think NP only said next please once during the call. Give him some credit hes trying

    (6)
  18. Enjay

    I was just getting ready to post the slides individually (very time-consuming) when I saw that CYDY

    (6)
  19. Number1Stocker

    I am curious about this too! Nice thought thank you!

  20. Number1Stocker

    Period!

    (1)
  21. StinkyPennies

    Two cool things stood out to me: unsolicited BP partnerships mentioned by SK + NP; and the fact

    (2)
  22. ohm20

    The company seems to me to have moved a bit more into focusing on building a database and a

    (8)
  23. Goosebumps

    I am extremely happy with the LHers results. Not that I expect it but even possible to have a

    (14)
  24. fsoalex

    This to me sounded like a different or re orientation for CytoDyn. It seemed to me that the

    (6)
  25. CDiddy

    That call seemed up beat and positive. I'm glad to hear that we have a time for HIV and that the

    (4)
  26. ohm20

    Make that 10 with clinical significance.

    (2)
  27. JLang

    My only real error here was assuming the US FDA was, even if not interested in saving lives, would

    (2)
  28. apoptree

    Mounting a COVID response may take immune system eye off any other latent viruses or dormant

    (10)
  29. Figgs

    If LL would be approved for severe/critical Covid19 with the 4 doses in a trial where it worked,

  30. grow

    I'm just correlating to the ranked list of most common symptoms. This trial lines up with

    (1)
  31. ohm20

    I believe it was 8 with statistical significance leaving 8 with clinical significance and 6 with no

    (1)
  32. ohm20

    Do you consider Vyera to be BP?

    (1)
  33. grow

    Seems to work on the top 7 long haulers symptoms plus many more IMO

  34. swordman

    so the vyera deal is not a good example??

    (1)
  35. Riztheinvestor

    Im listing right now and OHM is correct. BLA being handled outside of them and it makes sense if

    (2)
  36. Riztheinvestor

    Not sure how it normally works but good point.

  37. swordman

    I heard they would use different for oncology?? I hope you are right-- Only Dr Recknor

    (1)
  38. ohm20

    Amarex has the data. Last CC they said Dr. Recknor chose an outside group to do the

    (1)
  39. ohm20

    I highly doubt a BP will accept a deal for only one indication. They'll want control of all

    (2)
  40. swordman

    and Dr Recknor said he would be working with amarex to get info to complete BLA long way from

  41. Riztheinvestor

    No I think a partner isnt a bad idea.

    (5)
  42. ohm20

    They might become our overlords. :(

    (1)
  43. LaundryMoney

    My bad I should have used the phrase "drug Lords".

    (2)
  44. viridi

    Definitely sounds like goodbye to Amarex. And yet all we heard was what a good job they were

    (1)
  45. grow

    Leronlimab P2 study improves the most common symptoms for Covid19 long haulers. IMO the Leronlimab

    (4)
  46. ohm20

    Now you're using swear words too.

    (2)
  47. LaundryMoney

    Did I just hear what I thought I heard?? American regent kicked to the curb because they think Big

    (6)
  48. ohm20

    Why did Nader use a swear word in the CC?

    (1)
  49. Riztheinvestor

    Ill just say this for now. This was by far the best CC Ive heard since Ive been here.

    (13)
  50. ohm20

    Seperated from those that couldn't enroll one mTNBC patient in one year. Definitely sounds like

    (3)

Top 10 Most Recent News Articles

More News Articles

Top 5 Most Recently Viewed Articles

Match Group's Stock Outlook Remains Positive Ahead of Analyst Day

Updated Category News Views 158

Match Group's Strong Buy Rating from Analysts Recently, Deutsche Bank reaffirmed a Buy rating for Match Group (NASDAQ: MTCH) with a consistent price target of $45.00. Their assessment reveals a cautiously optimistic approach toward Tinder’s revenue figures, having adjusted estimates marginally lower by about 1%, placing anticipated revenue for the third quarter at $505...

Continue Reading
Myant Revolutionizes Disease Prevention at Arab Health Event

Updated Category News Views 276

Revolutionizing Healthcare Through Innovation At Arab Health 2025, Myant, a leader in healthcare innovation, is set to present its cutting-edge mission aimed at enabling human-centric, precise, and preventive care. This revolutionary vision is made possible through the integration of artificial intelligence and their unique approach to Textile Computing™, a breakthrough...

Continue Reading
Florida Politicians Clash Over Cannabis Legalization Efforts

Updated Category News Views 169

Florida's Cannabis Legalization Debate Intensifies The discussion about cannabis legalization in Florida has recently escalated, putting considerable pressure on local Republican leaders. Governor Ron DeSantis has shown frustration with members of his own party, calling for them to take a firmer stand against the cannabis legalization initiative known as Amendment 3. This...

Continue Reading
Tegna's Stock Surges Amid Nexstar Acquisition Talks

Updated Category News Views 461

Tegna's Exciting Surge in Stock Value Tegna Inc. (NYSE: TGNA) is currently at the center of attention as its stock undergoes a remarkable surge, primarily driven by the potential acquisition by Nexstar Media Group Inc. (NASDAQ: NXST). The transaction, which is reportedly in advanced stages, could redefine the landscape of the media industry. The Significance of the...

Continue Reading
Docusign's Upcoming Earnings Call: What Investors Should Know

Updated Category News Views 179

Docusign Prepares for a Key Earnings Report Mark your calendars, because Docusign’s fiscal fourth quarter results are about to drop like a hot potato! On March 17, 2026, after the market closes, it’s showtime for shareholders looking to make sense of this company's latest financial stomping ground. If you thought Docusign was just about signatures, think again—this...

Continue Reading